BaxDUO ARCTIC

a Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

Stadium
followup
Middel
Baxdrostat
Populatie
Primaire preventie coronairlijden
Fase
III
First Patient In
15 juli 2024
Last Patient In
21 november 2025
Last Patient Last Visit
10 december 2027

National Lead

J. van der Net

Studiedirecteur

dr. P.M. van der Zee

Cardioloog

Contact Kantoor

M.J. van Doorn

WCN

De pagina is verlopen.